Notably, these findings highlight the JAK2/STAT3/EPAS1 axis as a potential therapeutic target for asthma, offering new insights into its molecular mechanisms and identifying novel biomarkers for diagnosis and treatment. This evidence concerns the gene EPAS1 and asthma.